Boosting Drug Regulatory Efficiency: DCC recommends for Training and Development

Last Updated on October 18, 2024 by The Health Master

Drug Regulatory

In a significant move to enhance the effectiveness of drug regulatory officials across India, the Drugs Consultative Committee (DCC) has put forth several recommendations.

These recommendations aim to optimize training processes, support mechanisms, and overall performance standards within the drug regulatory framework.

Key Recommendations from the DCC

• Standardized Training Guidelines: The DCC has proposed the development of comprehensive guidelines for selecting candidates for training programs and evaluating their performance both before and after the training.
• Efficient Communication: Nomination details of participants for training programs should be communicated electronically to streamline the process and reduce administrative burdens.
• Enhanced Training Modules: The committee has recommended the creation of e-training modules and certification courses covering topics such as revised Schedule M, inspection, report writing, prosecution, and case studies.
• Regional Training Support: State Licensing Authorities should actively support regional training programs by assisting with venue selection, topic identification, and duration determination.
• Continuous Learning: To keep pace with advancements in the pharmaceutical, biological, and medical devices industries, the Training Cell of CDSCO has initiated a comprehensive training program for both CDSCO and state officials. This program includes tailored modules for various levels of induction, as well as basic and advanced courses.

Government Initiatives to Strengthen Drug Regulatory System

The Ministry of Health’s ‘Strengthening of States’ Drug Regulatory System (SSDRS)’ initiative, launched over a decade ago, has been instrumental in fortifying the drug regulatory infrastructure.

This scheme aims to introduce e-Governance, establish a training academy, and improve overall efficiency.

The Central government has also actively supported the strengthening of the drug regulatory system through various measures, including:

• Training Programs: The government has conducted 22 training programs for CDSCO and State Drug Control Officials in the financial year 2023-24.
• Financial Allocations: The Centre has approved Rs. 1,750 crore for strengthening drug regulatory structures at both the central and state levels.
• Infrastructure Upgradation: Funds have been released to support the provision of additional equipment, manpower, and new testing laboratories.

In conclusion, the recommendations put forth by the DCC, coupled with the government’s ongoing efforts, are expected to significantly enhance the efficiency and effectiveness of India’s drug regulatory system.

By investing in training, development, and infrastructure, the government aims to ensure the safety, quality, and efficacy of drugs and medical devices in the country.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

• Key Notes on Revised Schedule M: Point No. 11 – Personnel
  December 20, 2024
• USFDA issued Form 483 with two observations to Aurobindo for API plant
  December 20, 2024
• NPPA fixed retail price of 65 formulations: December 2024
  December 20, 2024
• Key Notes on Revised Schedule M: Point No. 10 – Self Inspection
  December 19, 2024
• Medical Device recall: USFDA classifies recall of these catheters as ‘most serious’
  December 19, 2024
• NPPA: New Strategy to Curb Drug Price Hikes
  December 19, 2024

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

For informative videos on consumer awareness, click on the below YouTube icon: